TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.
CARsgen Therapeutics Holdings Limited announced that it will present updated clinical data on its allogeneic CAR T-cell product candidate, CT0596, at the 67th Annual Congress of the American Society of Hematology in 2025. CT0596, developed using CARsgen’s proprietary THANK-u Plus™ platform, is being evaluated for relapsed/refractory multiple myeloma and plasma cell leukemia, showing promising tolerability and efficacy. The company plans further investigations into other plasma cell malignancies and autoimmune diseases, with an IND application anticipated in late 2025.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in areas such as hematologic malignancies, solid tumors, and autoimmune diseases. The company has developed comprehensive capabilities in CAR T-cell research and development, encompassing target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen is committed to improving the safety and efficacy of CAR T-cell therapies and reducing treatment costs, with a mission to become a global leader in providing innovative cell therapies.
Average Trading Volume: 2,487,701
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.82B
For an in-depth examination of 2171 stock, go to TipRanks’ Overview page.